1 Result: Annexon
Disappointing Results in Mirati Therapeutics' SAPPHIRE Study and Annexon's ARCHER Trial Lead to Stock Declines
May 24th, 2023
Mirati Therapeutics, Inc. (Nasdaq: MRTX) revealed disappointing news regarding the SAPPHIRE study, as it failed to meet its primary goal of overall survival in the final analysis. The Phase 3 study aimed to assess the effectiveness of sitravatinib, i. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login